Drug Profile
Research programme: cancer vaccines - Vaxon Biotech
Alternative Names: Vbx-016; Vbx-024; Vbx-025; Vbx-026; Vbx-027; Vbx-036Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Vaxon Biotech
- Class
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in France (IM, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in France (SC, Injection)
- 09 Oct 2015 Preclinical development is ongoing for Solid tumours